Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

New experimental pill, daraxonrasib, nearly doubled survival in metastatic pancreatic cancer patients, offering hope for a ...

Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, ...

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...

Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and ...

Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...

Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, announced results from two Phase 1/2 clinical trials evaluating ...